PMID- 20302683
OWN - NLM
STAT- MEDLINE
DCOM- 20100914
LR  - 20161020
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 31
IP  - 2
DP  - 2010 Mar-Apr
TI  - Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination 
      with an intranasal corticosteroid in seasonal allergic rhinitis.
PG  - 132-40
LID - 10.2500/aap.2010.31.3326 [doi]
AB  - The combination of intranasal antihistamines and intranasal corticosteroids 
      results in superior relief of seasonal allergic rhinitis (SAR) symptoms compared 
      with monotherapy. This study was designed to evaluate the safety and efficacy of 
      olopatadine hydrochloride nasal spray, 0.6% (OLO), administered in combination 
      with fluticasone nasal spray, 50 micrograms (FNS), relative to azelastine nasal 
      spray, 0.1% (AZE), administered in combination with FNS in the treatment of SAR. 
      This was a multicenter, double-blind, randomized, parallel-group comparison of 
      OLO + FNS versus AZE + FNS administered for 14 days to patients > or =12 years of 
      age with histories of SAR. Efficacy assessments recorded by patients in a daily 
      diary included nasal symptom scores. Safety was evaluated based on adverse events 
      (AEs). Pretreatment values for reflective total nasal symptoms scores (rTNSS) 
      were similar for both treatment groups. The mean (SD) 2-week average rTNSS was 
      4.28 (2.63) for OLO + FNS and 4.15 (2.63) for AZE + FNS; these scores were not 
      statistically different between treatment groups. No significant differences (p > 
      0.05) between OLO + FNS and AZE + FNS were observed for the average 2-week 
      percent changes from baseline in rTNSS or in the individual nasal symptoms (nasal 
      congestion, rhinorrhea, itchy nose, and sneezing). Compared with baseline, both 
      groups had statistically significant improvement in rTNSS (p < 0.05). No serious 
      AEs were reported in either group during the study period. Overall, 19 AEs were 
      reported in the OLO + FNS group and 29 AEs were reported in the AZE + FNS group. 
      OLO, when administered adjunctively with FNS, is effective, safe, and 
      well-tolerated in patients with SAR.
FAU - LaForce, Craig F
AU  - LaForce CF
AD  - North Carolina Clinical Research, Raleigh, North Carolina 27607, USA. 
      claforce@nccr.com
FAU - Carr, Warner
AU  - Carr W
FAU - Tilles, Stephen A
AU  - Tilles SA
FAU - Chipps, Bradley E
AU  - Chipps BE
FAU - Storms, William
AU  - Storms W
FAU - Meltzer, Eli O
AU  - Meltzer EO
FAU - Edwards, Michael
AU  - Edwards M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100318
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Androstadienes)
RN  - 0 (Dibenzoxepins)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Phthalazines)
RN  - 2XG66W44KF (Olopatadine Hydrochloride)
RN  - CUT2W21N7U (Fluticasone)
RN  - ZQI909440X (azelastine)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Androstadienes/*administration & dosage/adverse effects
MH  - Dibenzoxepins/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluticasone
MH  - Histamine Antagonists/*administration & dosage/adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Olopatadine Hydrochloride
MH  - Phthalazines/*administration & dosage/adverse effects
MH  - Rhinitis, Allergic, Seasonal/*drug therapy/physiopathology
MH  - Treatment Outcome
MH  - Ulcer/etiology
MH  - Xerostomia/etiology
EDAT- 2010/03/23 06:00
MHDA- 2010/09/15 06:00
CRDT- 2010/03/23 06:00
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2010/09/15 06:00 [medline]
AID - 3326 [pii]
AID - 10.2500/aap.2010.31.3326 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2010 Mar-Apr;31(2):132-40. doi: 10.2500/aap.2010.31.3326. 
      Epub 2010 Mar 18.